In addition, inhibition of tissue transglutaminase 2 (TG2) has demonstrated therapeutic benefits in animal models of HD, and PHB2 serves as a substrate for TG2, which may be involved in HD pathophysiological (122, 123). This evidence concerns the gene PHB2 and Huntington disease.